76,342 Shares in Veracyte, Inc. $VCYT Acquired by Campbell & CO Investment Adviser LLC

Key Points

• Campbell & CO Investment Adviser LLC has acquired 76,342 shares of Veracyte, Inc. (NASDAQ:VCYT), valued at approximately $2.26 million, representing 0.10% of the company's stock.
• Several institutional investors, including Versant Capital Management and Covestor Ltd, made significant increases in their holdings in Veracyte during the first quarter, highlighting increased institutional interest in the stock.
• Analyst ratings for Veracyte show an average rating of "Moderate Buy" with a target price of $40.90, although Morgan Stanley has set a lower price objective of $28.00, rating it "underweight."

Campbell & CO Investment Adviser LLC purchased a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 76,342 shares of the biotechnology company's stock, valued at approximately $2,264,000. Campbell & CO Investment Adviser LLC owned about 0.10% of Veracyte at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in Veracyte by 1,267.6% in the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock worth $28,000 after buying an additional 862 shares during the period. Headlands Technologies LLC purchased a new stake in Veracyte in the 1st quarter worth approximately $48,000. GF Fund Management CO. LTD. purchased a new stake in Veracyte in the 4th quarter worth approximately $64,000. Covestor Ltd lifted its holdings in Veracyte by 23,936.4% in the 1st quarter. Covestor Ltd now owns 2,644 shares of the biotechnology company's stock worth $78,000 after buying an additional 2,633 shares during the period. Finally, Captrust Financial Advisors purchased a new stake in Veracyte in the 4th quarter worth approximately $206,000.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on VCYT shares. Morgan Stanley set a $28.00 price objective on Veracyte and gave the stock an "underweight" rating in a report on Friday, August 8th. Needham & Company LLC dropped their price objective on Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a report on Thursday, May 8th. UBS Group lowered their target price on Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded Veracyte from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $40.90.

Veracyte Stock Up 5.3%

VCYT opened at $31.00 on Monday. The stock has a market cap of $2.44 billion, a PE ratio of 93.94 and a beta of 1.97. The business has a 50 day moving average of $26.60 and a 200-day moving average of $29.86. Veracyte, Inc. has a 52 week low of $22.61 and a 52 week high of $47.32.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.